Clinical data supports the use of stem cells for skin rejuvenation.
Preclinical data from Turn Biotechnologies demonstrated that the company’s mRNA-based ERA (Epigenetic Reprogramming of Aging) technology rejuvenates skin cells more effectively and safely than existing treatments. ERA rejuvenates cells without disrupting cellular identity by targeting epigenomes (chemical compounds that tell cells what to do) to restore cell function, using mRNA to deliver transcription factors to the epigenome.
